


ONCOLOGY DRUG DISCOVERY

- ▶ Leading expertise in tumour immuno-environment, metabolism, DNA repair and epigenetics
- ▶ Critical mass of >100 scientists focussing on oncology research
- ▶ Established network of clinicians and pathologists for access to patient material
- ▶ CRISPR platform for target discovery and validation
- ▶ Rational design of novel targeted therapies



AREAS OF EXPERTISE

Employed to generate drug candidates as single agents, in combination with SoC and targeted therapies & alongside immune checkpoint inhibitors

IMMUNO-ONCOLOGY

Targeting mechanisms of immunosuppression

TUMOR MICROENVIRONMENT

Targeting cells within the tumor microenvironment

EPIGENETICS

Targeting mechanisms underpinning tumour survival

DNA REPAIR

Targeting pathways tumors use to evade lethal genomic damage

Evotec provides its partners with a full range of drug discovery & development services and also invests in proprietary early stage discovery programmes (including in DNA damage response) for strategic partnering with pharma and biotech companies.

IN VITRO BIOLOGY

- ▶ Extensive portfolio of assay for oncology targets including metabolic enzymes, kinases, PPIs and immune receptors supporting drug discovery integrated projects
- ▶ Customised high-content imaging assays for phenotypic screening and lead optimisation support, & target ID approaches via small molecules, RNAi or CRISPR screens
- ▶ Specific assays to study drug resistance, cancer metabolism or tumour microenvironment (immune cells, fibroblasts, adipocytes, endothelial cells etc.)
- ▶ All oncology assays (imaging, invasion, proliferation, cancer/immune cell co-culture) are compatible with our versatile CRISPR screening platform

IN VIVO PHARMACOLOGY


- ▶ Establishment of PK/PD relationships using target engagement or surrogate markers
- ▶ Syngeneic, orthotopic tumour xenografts to track anti-tumour and microenvironment effects, including Immuno-profiling for Drug MoA & humanised mouse model system for evaluation of immune modulation agents
- ▶ Discovery toxicology platform incorporating histology, blood biochemistry, haematology and safety biomarkers

BIOMARKERS


- ▶ TLDA-based/RNA-Seq gene signature analysis supported by bioinformatics tools for data mining and pathway analysis
- ▶ Leading MS-based proteomics, metabolomics and lipidomics for target deconvolution, MoA studies and biomarker discovery
- ▶ Establishment of protocols for transfer to clinic, including Ventana IHC platform, flow cytometry and ELISA with access to patient material for biomarker validation and *ex vivo* studies

HYPOTHESIS-DRIVEN DRUG DESIGN-DRIVEN MEDICINAL CHEMISTRY


- ▶ Experienced structural biology, computational, DMPK & medicinal chemistry teams working in synergy to optimise phenotypic and biochemical screening hits through rapid iterative cycles



High Content imaging



IHC of hypoxia



T cell proliferation